Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PURPOSE: Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated improved survival in previously treated patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I, multicohort study, was conducted to explore the s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Rizvi, Naiyer A., Hellmann, Matthew D., Brahmer, Julie R., Juergens, Rosalyn A., Borghaei, Hossein, Gettinger, Scott, Chow, Laura Q., Gerber, David E., Laurie, Scott A., Goldman, Jonathan W., Shepherd, Frances A., Chen, Allen C., Shen, Yun, Nathan, Faith E., Harbison, Christopher T., Antonia, Scott
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569693/
https://ncbi.nlm.nih.gov/pubmed/27354481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.66.9861
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados